BIOGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
BIOGEN INC. (BIIB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.90 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2023-02-15
- BIOGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $2.90M, a 30.95% decline from fiscal 2019.
- BIOGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $4.20M, a 5.00% increase from fiscal 2018.
- BIOGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $4.00M, a 17.65% increase from fiscal 2017.
- BIOGEN INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $3.40M, a 67.31% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2020-12-31 | $2.90M 10-K · filed 2023-02-15 |
| 2019-12-31 | $4.20M 10-K · filed 2022-02-03 |
| 2018-12-31 | $4.00M 10-K · filed 2021-02-03 |
| 2017-12-31 | $3.40M 10-K · filed 2020-02-06 |
| 2016-12-31 | $10.40M 10-K · filed 2019-02-06 |
| 2015-12-31 | $38.00M 10-K · filed 2018-02-01 |
| 2014-12-31 | $42.70M 10-K · filed 2017-02-02 |
| 2013-12-31 | $86.20M 10-K · filed 2016-02-03 |
| 2012-12-31 | $63.00M 10-K · filed 2015-02-04 |
| 2011-12-31 | $149.00M 10-K · filed 2014-02-06 |
| 2010-12-31 | $50.50M 10-K · filed 2013-02-05 |
| 2009-12-31 | $6.70M 10-K · filed 2012-02-03 |
| 2008-12-31 | $85.10M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |